1 一场精妙的“四步资本魔术”中国生物制药(以下简称“中生制药”)收购礼新医药的交易,表面看是本土药企龙头对创新Biotech的战略并购,实则上演了一场精心设计的“资本循环游戏”。通过拆解其运作链条,可清晰看到四个精密衔接的资本操作阶段:低价卡位(2024年8月):根据工商信息,中生制药以124.8253万元人民币注资礼新医药,获得4.9084%股权。按注资比例推算,此时礼新医药整体估值仅约...
Source Link1 一场精妙的“四步资本魔术”中国生物制药(以下简称“中生制药”)收购礼新医药的交易,表面看是本土药企龙头对创新Biotech的战略并购,实则上演了一场精心设计的“资本循环游戏”。通过拆解其运作链条,可清晰看到四个精密衔接的资本操作阶段:低价卡位(2024年8月):根据工商信息,中生制药以124.8253万元人民币注资礼新医药,获得4.9084%股权。按注资比例推算,此时礼新医药整体估值仅约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.